Ovarian cancer is often called a “silent disease” because its symptoms can be subtle and easily overlooked. While factors such as age, lifestyle, and reproductive history may influence risk, genetics plays a crucial role in understanding who may be more vulnerable. Among the most significant genetic factors linked to ovarian cancer are mutations in the BRCA1 and BRCA2 genes.
BRCA1 and BRCA2 are genes that naturally help repair damaged DNA and ensure cells grow in a healthy, controlled manner. In this sense, they act as the body’s natural defence against cancer. However, when mutations occur in these genes, their ability to repair DNA is impaired. This increases the likelihood of abnormal cell growth, which can lead to cancers, particularly ovarian and breast cancer.
Women who inherit harmful mutations in BRCA1 or BRCA2 have a significantly higher risk of developing ovarian cancer compared to the general population. According to the National Cancer Institute (USA), the lifetime risk of ovarian cancer is estimated to be about 39–44% for BRCA1 mutation carriers and 11–17% for BRCA2 mutation carriers, compared to roughly 1–2% in the general population. These figures highlight the importance of recognising genetic risk factors early.
It is important to understand that BRCA mutations are inherited, meaning they can be passed down from either parent. A family history of ovarian, breast, or related cancers may indicate the possibility of such mutations. However, not all individuals with a family history will carry the mutation, and not all mutation carriers will develop cancer. This is why genetic counselling and testing play a vital role in risk assessment and informed decision-making.
Early detection of ovarian cancer remains challenging, which makes awareness even more critical. Symptoms such as persistent bloating, pelvic pain, difficulty eating, or frequent urination are often mistaken for less serious conditions. For individuals with a known genetic risk, regular medical consultations, screening strategies, and preventive measures can significantly improve outcomes.
Advancements in medical science have made it possible to take proactive steps for those at higher genetic risk. These may include enhanced surveillance, lifestyle modifications, and in some cases, preventive treatments or surgeries. Additionally, targeted therapies, such as PARP inhibitors, have shown promise in treating cancers associated with BRCA mutations by specifically addressing the underlying genetic weakness in cancer cells.
At Child Help Foundation (CHF), we believe that awareness and education are key to prevention and early intervention. By spreading knowledge about genetic risks, such as BRCA mutations, we aim to encourage individuals and families to seek timely medical advice and make informed health choices. Understanding one’s risk can lead to earlier diagnosis, better treatment options, and improved survival rates.
Equally important is breaking the stigma around discussing cancer and genetic health. Open conversations within families and communities can help identify risks sooner and ensure that individuals receive the care and support they need. Access to accurate information empowers people to take control of their health and supports a proactive approach to well-being.
In conclusion, while genetics cannot be changed, awareness can make a life-saving difference. Recognising the role of BRCA mutations in ovarian cancer enables early detection, informed decisions, and better outcomes. Through continued education and community engagement, we can move towards a future where fewer lives are affected by this disease and more individuals are empowered to protect their health.